Reply to Kovesi, to Chabra, and to Farber: “Palivizumab Prophylaxis and Recurrent Wheezing” and “Precise Gestational Age Definitions Needed for Palivizumab Prophylaxis in Preterm Infants” and “Imbalance in Level of Tobacco Smoke Exposure Between Groups Likely Explains the “Effect” of Palivizumab on Subsequent Wheezing”